Comparison between Q-Line Biotec IPO and Vectras Enprocon IPO.
Q-Line Biotec IPO is a SME Bookbuilding IPO proposed to list at NSE SME while Vectras Enprocon IPO is a SME Bookbuilding proposed to list at BSE SME.
The total issue size of Q-Line Biotec IPO is up to ₹0.00 Cr whereas the issue size of the Vectras Enprocon IPO is up to ₹0.00 Cr. The final issue price of Q-Line Biotec IPO is and of Vectras Enprocon IPO is .
| Q-Line Biotec IPO | Vectras Enprocon IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ||
| Issue Price (Upper) | ||
| Issue Price (Final) | ||
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | ||
| Fresh Issue Size | 70,53,200 shares | 50,00,000 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| OFS Issue Size | 0 shares | 10,00,000 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 70,53,200 shares | 60,00,000 shares |
| Issue Size Total (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
Q-Line Biotec IPO opens on , while Vectras Enprocon IPO opens on . The closing date of Q-Line Biotec IPO and Vectras Enprocon IPO is , and , respectively.
Q-Line Biotec IPO P/E ratio is , as compared to Vectras Enprocon IPO P/E ratio of .
| Q-Line Biotec IPO | Vectras Enprocon IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)Q-Line Biotech Ltd.'s revenue increased by 56% and profit after tax (PAT) dropped by 18% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated)Vectras Enprocon Ltd.'s revenue increased by 48% and profit after tax (PAT) rose by 75% between the financial year ending with March 31, 2025 and March 31, 2024.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 96.77 | 100 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 17.66 | 59.00 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 23.74 | 55.94 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.87 | 0.53 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 23.74 | 59.00 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Q-Line Biotec IPO Retail Individual Investors (RII) are offered 0 shares while in Vectras Enprocon IPO retail investors are offered 0 shares. Qualified Institutional Buyers (QIB) are offered 0 shares in Q-Line Biotec IPO and 0 shares in Vectras Enprocon IPO.
| Q-Line Biotec IPO | Vectras Enprocon IPO | |
|---|---|---|
| Anchor Investor Reservation | 0 shares | 0 shares |
| Market Maker Reservation | 0 shares | 0 shares |
| QIB | 0 shares | 0 shares |
| NII | 0 shares | 0 shares |
| RII | 0 shares | 0 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 0 shares | 0 shares |
Q-Line Biotec IPO subscribed in total, whereas Vectras Enprocon IPO subscribed .
